The currently practiced targeted therapy fails to eliminate the complete population of CML progenitor cells having ABL kinase domain mutation that leads to imatinib resistance; hence, our interest is to explore the targets outside this domain. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.